Niacin Boosts Immune Response in Glioblastoma Trial

University of Calgary researchers are testing high-dose vitamin B3 (niacin) in addition to standard glioblastoma treatment. Early Phase I/II results in 24 patients show 82% progression-free at six months, a 28% improvement over historical data, suggesting niacin may restore immune function to attack tumors. Safety monitoring remains essential, and enrollment will expand to 48 participants by 2026–2027 to confirm benefits.